X

Trial Profile

A phase I trial assessing MD-7246 targeting visceral pain associated with Irritable bowel syndrome with diarrhea (IBS-D)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linaclotide (Primary)
Indications Constipation; Irritable bowel syndrome; Visceral pain
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

18 Feb 2020 Status changed from planning to recruiting.
06 Nov 2019 New trial record
28 Oct 2019 According to an Ironwood Pharmaceuticals media release, data from this study will be presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting being held in San Antonio, TX, October 25 through October 30, 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com